L-citrulline for erectile dysfunction has moved from bodybuilding forums into the peer-reviewed literature, and the reason is mechanistic rather than promotional: the amino acid feeds directly into the nitric oxide pathway that governs penile blood flow. An erection is, at its core, a vascular event. When nitric oxide (NO) signalling is intact, the smooth muscle of the corpora cavernosa relaxes, arterial inflow rises, and rigidity follows. When that signalling is blunted, erectile function suffers. L-citrulline is interesting precisely because it raises the raw material the body uses to make NO. This article reviews what the controlled evidence actually demonstrates, where the biology is strong, and where expectations should be tempered.
The nitric oxide pathway and the erectile response
Penile erection depends on a tightly choreographed sequence. Sexual stimulation triggers nerve endings and the vascular endothelium to release nitric oxide, which activates the enzyme guanylate cyclase. That enzyme produces cyclic guanosine monophosphate (cGMP), the second messenger that relaxes cavernosal smooth muscle. As the muscle relaxes, blood floods the erectile tissue and compresses the veins that would normally drain it, trapping blood and producing rigidity. The enzyme phosphodiesterase type 5 (PDE5) breaks cGMP back down, ending the erection.
This is the exact pathway that PDE5 inhibitors such as sildenafil and tadalafil target: they block the breakdown of cGMP, prolonging its effect. But PDE5 inhibitors do nothing to increase the upstream supply of nitric oxide. If endothelial NO production is impaired, as it commonly is in men with vascular risk factors such as hypertension, diabetes, or atherosclerosis, there may simply be less cGMP being generated in the first place. This is one reason a meaningful subset of men respond only partially to PDE5 therapy. L-citrulline is relevant here because it works on the supply side of the same equation.
Why L-citrulline outperforms L-arginine on paper
The body synthesises nitric oxide from the amino acid L-arginine, so it would seem logical to simply supplement arginine directly. In practice, oral L-arginine is a surprisingly inefficient way to raise circulating arginine. A large fraction is degraded in the gut and liver by the enzyme arginase before it ever reaches the systemic circulation, a phenomenon known as extensive presystemic elimination.
L-citrulline sidesteps this bottleneck. It is absorbed efficiently in the small intestine, bypasses hepatic first-pass metabolism, and is then converted to L-arginine in the kidneys. The result is counterintuitive but well documented: oral L-citrulline raises plasma L-arginine levels more effectively than an equivalent dose of L-arginine itself. In a controlled pharmacokinetic study, Schwedhelm and colleagues found that citrulline produced a greater increase in the plasma arginine area-under-the-curve than arginine did, and augmented nitric-oxide-dependent signalling in a dose-dependent manner [1]. For anyone trying to increase NO availability, citrulline is the more rational precursor. Clinical studies suggest this bioavailability advantage is the foundation for any downstream erectile benefit.
What the erectile function trials show
The most cited clinical evidence comes from a single-blind study by Cormio and colleagues in men with mild erectile dysfunction. Participants received 1.5 grams of L-citrulline daily for one month. The proportion of men achieving a normal erection hardness score rose from 8 percent on placebo to 50 percent on citrulline, and treatment satisfaction increased accordingly [2]. The authors were careful to frame the effect as modest relative to PDE5 inhibitors, but the safety profile was excellent and no adverse events were reported. For men with mild symptoms who are reluctant to start pharmaceutical therapy, that risk-to-benefit ratio is notable, though the study was small and not double-blinded.
The more clinically interesting question is what happens when citrulline is combined with a PDE5 inhibitor. Because the two act on opposite ends of the NO–cGMP axis, one increasing cGMP production and the other slowing its breakdown, there is a plausible additive rationale. A randomized, double-blind, placebo-controlled crossover study by Shirai and colleagues examined L-citrulline combined with transresveratrol as an adjunct in men taking PDE5 inhibitors, and reported improved erectile function scores compared with the inhibitor alone [3]. The signal was preliminary and the sample small, but it aligns with the underlying pharmacology and has prompted larger combination trials now underway.
The vascular argument: endothelial function and arterial health
Erectile dysfunction is frequently an early warning sign of systemic endothelial dysfunction, sometimes preceding a cardiac event by years. Any intervention that improves endothelial performance is therefore relevant to erectile health for reasons that extend beyond the bedroom.
Here the citrulline evidence is broader. Beyond the erectile-specific trials, L-citrulline supplementation has been shown in controlled studies to improve flow-mediated dilation, a standard measure of endothelial function, and to modestly reduce arterial stiffness and blood pressure in adults with cardiometabolic risk [4]. For comparison, long-term high-dose L-arginine has also demonstrated benefit in vasculogenic erectile dysfunction in a multicentre randomized trial, reinforcing that the arginine–NO axis is a legitimate therapeutic target rather than a fringe idea [5]. Because the corpora cavernosa are lined with the same type of endothelium found in coronary and peripheral arteries, improvements measured in the brachial artery are a reasonable proxy for improvements in penile vascular responsiveness. Some men experience the erectile benefit as part of a wider improvement in vascular tone rather than as an isolated effect.
Practical considerations, dosing, and limits
The doses used in erectile and vascular studies typically range from 1.5 to 6 grams of L-citrulline per day, often taken as a single dose or split. Effects on plasma arginine appear within an hour or two, but the clinical erectile benefit in trials accrued over several weeks of consistent use, consistent with a gradual improvement in endothelial function rather than an acute, on-demand effect. This is an important expectation to set: L-citrulline is not a substitute for the rapid, reliable action of a prescription PDE5 inhibitor.
Two honest caveats apply. First, the erectile-specific trial base is small and, in the landmark study, not fully blinded, so the effect size should be treated as promising rather than definitive. Second, men taking nitrates for heart disease, or those on antihypertensive medication, should not combine NO-boosting supplements with prescription therapy without physician oversight, because the blood-pressure-lowering effects can stack. The most defensible use of L-citrulline is within a supervised plan that also addresses the underlying vascular drivers of erectile dysfunction, rather than as a standalone fix bought online.
Conclusion
L-citrulline occupies a logical and evidence-supported position in the erectile function conversation. It targets the supply side of the nitric oxide pathway, it is more bioavailable than L-arginine, and it has controlled data showing benefits for both erection hardness and endothelial function. It is not a replacement for PDE5 inhibitors, and the strongest emerging rationale is combination rather than monotherapy, pairing an upstream NO precursor with a downstream cGMP protector. Read alongside the wider vascular literature on our blog, citrulline is best understood as one component of a comprehensive, vascular-first approach to men's sexual health.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including on-demand protocols such as Red Pill that combine tadalafil with the nitric-oxide-supporting antioxidant Pycnogenol. Every plan starts with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. British Journal of Clinical Pharmacology. 2008;65(1):51-59. doi:10.1111/j.1365-2125.2007.02990.x
- Cormio L, De Siati M, Lorusso F, et al. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77(1):119-122. doi:10.1016/j.urology.2010.08.028
- Shirai M, Hiramatsu I, Aoki Y, et al. Oral L-citrulline and transresveratrol supplementation improves erectile function in men with phosphodiesterase 5 inhibitors: a randomized, double-blind, placebo-controlled crossover pilot study. Sexual Medicine. 2018;6(4):291-296. doi:10.1016/j.esxm.2018.07.001
- Allerton TD, Proctor DN, Stephens JM, et al. l-Citrulline supplementation: impact on cardiometabolic health. Nutrients. 2018;10(7):921. doi:10.3390/nu10070921
- Menafra D, de Angelis C, Garifalos F, et al. Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. Journal of Endocrinological Investigation. 2022;45(5):941-961. doi:10.1007/s40618-021-01704-3
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.